REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.26
-0.38 (-3.89%)
Nov 21, 2024, 12:28 PM EST - Market open
REGENXBIO Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for REGENXBIO stock have an average target of 36.36, with a low estimate of 18 and a high estimate of 52. The average target predicts an increase of 292.87% from the current stock price of 9.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for REGENXBIO stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 6 | 6 | 5 | 6 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +461.86% | Nov 20, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $22 | Buy | Initiates | $22 | +137.71% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +332.20% | Nov 7, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +461.86% | Oct 22, 2024 |
| Raymond James | Raymond James | Buy Initiates $18 | Buy | Initiates | $18 | +94.49% | Oct 10, 2024 |
Financial Forecast
Revenue This Year
97.38M
from 90.24M
Increased by 7.91%
Revenue Next Year
306.51M
from 97.38M
Increased by 214.75%
EPS This Year
-4.82
from -6.02
EPS Next Year
-1.09
from -4.82
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 147.8M | 422.7M | 627.9M | ||
| Avg | 97.4M | 306.5M | 261.9M | ||
| Low | 75.6M | 195.0M | 103.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 63.8% | 334.1% | 104.9% | ||
| Avg | 7.9% | 214.8% | -14.6% | ||
| Low | -16.3% | 100.3% | -66.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.53 | 1.87 | -2.77 | ||
| Avg | -4.82 | -1.09 | -3.71 | ||
| Low | -4.85 | -3.07 | -5.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.